Memo Therapeutics AG

Our CFO Lars Spenger and VP Commercial Strategy, Alexander Bastian are attending the 30th annual #BIOEurope conference in Stockholm, Sweden from 4-6 November.   As our Phase II clinical trial progresses for potravitug, our lead asset targeting BK viremia in kidney transplant patients, we are looking forward to connecting with industry leaders and investors as we prepare to become a Phase III ready organization.   Find the full conference agenda here: https://lnkd.in/dnuNZ2D   #BIOEurope #Networking #30years #MemoTherapeuticsAG #MTx #Biotech

Our goal is to transform the lives of patients with viral infections and cancer by developing best-in-class therapeutic antibodies, therefore patients are at the core of our work and #research.   Meet Kevin Fowler our patient advocate consultant and Principal of ‘The Voice of the Patient’, a patient advocacy and engagement consulting business.   In this #spotlight Q&A, Kevin takes us through his personal journey with kidney disease, how it led to his involvement in patient advocacy and the important role that biotech companies have in properly catering to the needs of kidney disease patients.   Flip through the full Q&A below or on our website here: https://lnkd.in/ejnt2UzZ   #EmployeeSpotlight #AntibodyDiscovery #BiotechInnovation #BehindTheScenes #MemoTherapeuticsAG #MTx #Biotech

We will be presenting a poster in collaboration with Maja Kuharic from Northwestern University and Kevin Fowler on the burden of BK polyomavirus infection in kidney transplant recipients at the Annual American Society of Nephrology #ASNKidney Meeting in San Diego, California, USA.   Our CEO, Erik van den Berg, CMO, Juergen Beck, VP Commercial Strategy, Alexander Bastian and VP Clinical Operations, Kristie Bass Clemmer will be in attendance.   Poster title: Burden of BK Virus Infection and BK Virus-Associated Nephropathy in Kidney Transplant Recipients: Scoping Review Reveals Gaps in Patient-Centered Research Date: October 26, 2024 | 10:00 AM Location: Exhibit Hall, Convention Center   Learn more about our work in developing best-in-class therapeutic antibodies for viral infections and cancer here: https://lnkd.in/ebCsH5TM   #KidneyWeek #KidneyDisease #MemoTherapeuticsAG #MTx #AntibodyDiscovery #Nephrology #DrugDiscovery #Innovation

Our CFO, Lars Spenger will be at Sachs Associates Annual Biotech in Europe Forum in Basel, Switzerland.   On the back of a recent series C extension of CHF 20 million and several new additions to our management team, we are rapidly becoming a Phase III ready organization with our lead asset, potravitug, currently in a Phase II clinical trial.   If you would like to speak to Lars, please contact us at: info@memo-therapeutics.com. #MemoTherapeuticsAG #MTx #Biotech #AntibodyDiscovery #InfectiousDiseases #Cancer #Innovation #VentureCapital #Partnering

We are proud to have a talented team who are driven by a common purpose to transform the lives of patients with viral infections and cancer through best-in-class therapeutic antibodies.   Meet Matthieu Delincé, our Director of Oncology Research, who is spearheading Memo Therapeutics AG’s efforts to improve cancer treatments. In this #spotlight Q&A, we delve into Matthieu’s background and how he and his team use our proprietary DROPZYLLA® technology to identify novel antibody-target pairs for the treatment of solid tumours.   Read the full Q&A here: https://lnkd.in/eB2iia6s    #EmployeeSpotlight #AntibodyDiscovery #BiotechInnovation #BehindTheScenes #MemoTherapeuticsAG #MTx #Biotech 

The Memo Therapeutics AG team, Erik van den Berg, Alexander Bastian and Matthieu Delincé will be present at ESMO - European Society for Medical Oncology Congress 2024 from 13-17 September in Barcelona Spain.   Join us in Barcelona as we engage in meaningful discussions and explore innovative solutions. We are currently using our proprietary DROPZYLLA® discovery platform to identify antibodies in elite patients to develop targeted cancer therapies.   Find the full agenda for the congress here: https://lnkd.in/eytECTz8   #ESMO2024 #MemoTherapeuticsAG #MTx #AntibodyDiscovery #Oncology #DrugDiscovery #Innovation  

Our CEO Erik van den Berg has been featured on the latest #BusinessOfBiotech #podcast with Matthew Pillar!   With approaching 30 years of experience embracing the chaos of #biotech, Erik offers invaluable insights into navigating our dynamic industry, including keeping development on track through bull and bear markets and creating differentiation in crowded therapeutic spaces.   Tune in to hear how Memo Therapeutics AG is charting its course through the exciting, ever-changing biotech landscape on YouTube here: https://lnkd.in/e4HCTA-S    Also available on Spotify/Apple podcasts: https://lnkd.in/ejkdutGC   #Leadership #MemoTherapeuticsAG #AntibodyDiscovery #BiotechInnovation

Memo Therapeutics AG’s CEO and CSO, Erik van den Berg and Christoph Esslinger, are at THE ANTIBODY SERIES conference this week.   Amongst leading experts in antibody discovery, we look forward to insightful discussions.   Learn more about our proprietary antibody discovery platform here: https://lnkd.in/ehvyPchc   #AntibodySeries #AntibodyDiscovery #Innovation #Networking #Biotech #MemoTherapeuticsAG #MTx

We recently sat down with Simone Schmitt our VP Technology and Operations and delved into her extensive career in antibody discovery and development. She shared her journey from academia to biotech and explains how Memo Therapeutics AG is pioneering the field of antibody discovery for viral infections and cancer with our technology.   Read Simone’s full #spotlight interview on our website here: https://lnkd.in/eF_mrugN   #EmployeeSpotlight #AntibodyDiscovery #BiotechInnovation #MemoTherapeuticsAG #Biotech  

We are pleased to welcome Alexander Bastian as our new VP Commercial Strategy.   Alex joins us from AM-Pharma, bringing extensive experience in commercial leadership, market access, and patient advocacy. His expertise will be crucial as we prepare for Phase III of our lead program Potravitug, a BKV-neutralizing antibody for BK virus infection in kidney transplant patients.   Read more about Alex’s appointment here: https://lnkd.in/egUPAFjg #MemoTherapeuticsAG #MTx #Biotech #AntibodyDiscovery #InfectiousDiseases #Innovation #NewHire